The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy of nirogacestat in participants with poor prognostic factors for desmoid tumors: Analyses from the randomized phase 3 DeFi study.
 
Bruno Vincenzi
Consulting or Advisory Role - abbott; GlaxoSmithKline; Lilly
Speakers' Bureau - PharmaMar
Research Funding - BD Bard
 
Nam Bui
Consulting or Advisory Role - Rain Therapeutics; SpringWorks Therapeutics
 
Palma Dileo
No Relationships to Disclose
 
Noah Federman
Stock and Other Ownership Interests - Moderna Therapeutics
Consulting or Advisory Role - Bayer; SpringWorks Therapeutics
Speakers' Bureau - Bayer; Fennec Pharma; Springworks Therapeutics
Research Funding - Mirati Therapeutics
 
Richard F. Riedel
Employment - Limbguard (I)
Leadership - Limbguard (I)
Stock and Other Ownership Interests - Limbguard (I)
Consulting or Advisory Role - AADi; Adaptimmune; Blueprint Medicines; Boehringer Ingelheim; Daiichi Sankyo; Deciphera; GlaxoSmithKline; NanoCarrier; SpringWorks Therapeutics
Research Funding - AADi (Inst); Arog (Inst); Ayala Pharmaceuticals (Inst); BioAtla (Inst); Blueprint Medicines (Inst); Cogent Biosciences (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); InhibRx (Inst); NanoCarrier (Inst); Oncternal Therapeutics (Inst); Philogen (Inst); PTC Therapeutics (Inst); SpringWorks Therapeutics (Inst); TRACON Pharma (Inst); Trillium Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - PandoNet - Limbguard (I)
Travel, Accommodations, Expenses - Daiichi Sankyo; Deciphera; NanoCarrier; SpringWorks Therapeutics
 
Brian Andrew Van Tine
Leadership - Polaris
Honoraria - Iterion Therapeutics, Inc; Total Health Conference
Consulting or Advisory Role - Aadi; Acuta Capital Partners, LLC; ADRx; Advenchen Laboratories; Agenus; Ayala Pharmaceuticals; Bayer; Boehringer Ingelheim; Boxer Capital LLC; Curis; Daiihi Sankyo; Deciphera; Deciphera Pharmaceuticals,; EcoR1 Capital; Epizyme; Hinge Bio, Inc.; Intellisphere; Kronos Bio, Inc.; PTC Therapeutics; PTC Therapeutics; Putnam Associates; Race Oncology; Regeneron; Salarius Pharmaceuticals, Inc.,
Research Funding - GlaxoSmithKline; Merck; Pfizer; Polaris; TRACON Pharma
Patents, Royalties, Other Intellectual Property - Accuronix Therapeutics- Licensing agreement. Sigma-2 Receptor Ligands and Therapeutic uses therefor (006766), • Modular Platform for Targeted Therapeutic Delivery (006755), • Sigma-2 Receptor Ligand Drug Conjugates as Antitumor Compounds, Methods of synth; Patent on ALEXT3102; Patent on the use of ME1 as a biomarker
Expert Testimony - Health Advances
Travel, Accommodations, Expenses - Adaptimmune; Advenchen Laboratories; Kronos Bio, Inc
 
Vincent Amoruccio
Employment - SpringWorks Therapeutics
 
Allison Lim
Employment - SpringWorks Therapeutics
Stock and Other Ownership Interests - SpringWorks Therapeutics
 
Ana B. Oton
Employment - SpringWorks Therapeutics
Stock and Other Ownership Interests - SpringWorks Therapeutics
 
Bernd Kasper
Honoraria - Bayer; GlaxoSmithKline; Pharmamar-zeltia
Consulting or Advisory Role - Ayala Pharmaceuticals; Bayer; Boehringer Ingelheim; GlaxoSmithKline; SpringWorks Therapeutics
Research Funding - Ayala Pharmaceuticals (Inst); Cogent Medicine (Inst); PharmaMar (Inst); SpringWorks Therapeutics (Inst)